The scientific discussion is very impressive...tell us why the stock is at 18 cents CAD with a 30M market cap after a FDA fast track, whilst other CAD bio like say TRIL is at $23 CAD with a 2B market cap and MMED is at $2.50 CAD with a 725M valuation?
Time somebody starting asking, "what the deal is"...and I don't mean the next financing.
I expect this to grind now into tax loss season and the escort will be this bullboard...watch ; - )